Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dear Miss Scarlet,
Thank you for the education.
Big Blue
Dear Extreme,
As others have eloquently voice you should take care not to post any altered snippets of company related information. Your intent seemed rather transparent; however, regardless of intent you still should be wary of misrepresenting company documents. There is more than 1 organization that could find fault here. Ignorance and / or intent are rarely defensible stances if your play was spotlighted on a grander stage. Simply put, the consequence of your actions could be elevated to more than members of this board telling you how they feel about your post. Why take the chance.
Big Blue
Thanks Money.
Big Blue
OT: I was wondering if the board could help me out...
I am looking for sub $5 per share US traded companies in the field of Pharmacogenetics and Genomics that the board could suggest / recommend. All suggestions are appreciated. Thank you in advance.
Big Blue
New Information / Patent
As promised, I stated that I would update the board from time to time on DNAP Patent movement. By the term movement I mean that there has been another step initiated by DNAP or the US Patent Office. This movement may be a non-final rejection, responses, forwarding information, etc. However, movement means that we are closer to the potential of getting a patent. I hope the board finds this information helpful.
Big Blue
Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data
US: 09/964,059; Movement on: 04-01-2005
Methods for the Identification of Genetic Features for Complex Genetics Classifiers
US: 10/120/804; Movement on: 05-04-2005
Compositions and Methods for Detecting Polymorphisms Associated with Pigmentation
US: 10/156,995; Movement on: 04-04-2005
Compositions and Methods for Inferring a Response to Statin
US: 10/188,359; Movement on: 03-30-2005
Hi Cosmic,
Thank you for the private email. Since I have a free membership I have to respond here. It seems that we are looking at this company in much the same way. I wish you and all the best of luck.
God bless to you too,
Big Blue
mikenickels,
You can increase shares without doing a r/s. At this stage I would rather increase shares proportionally to a two year need. With products in the pipeline the need could change if pps increase along with earnings.
Big Blue
Hi Frogdreaming,
As to your follow-up:
Share dilution with the Dutchess Agreement will provide DNAP with 35 million.
Could you please elaborate? my concern lies with the current market cap. As there does not appear to be any significant change in the status quo on the short term horizon, it seems to be a fairly large inconsistency to expect to extract $35 million via a dilutive process from a company valued at less than half that amount.
-I agree with you that there is an inconsistency as per the needed capital compared to extracting it from the current pps. Therefore, it is very likely that one, some, or all of three things would need to happen: either a r/s (vote on), an increase in shares(vote on), or an increase in the pps.
As to your second question:
So it is likely that any push for a r/s is for greater returns for share dilution. As of right now I probably will not be voting for a r/s.
Given that the Dutchess $35 Million Agreement will require sufficient shares to support it, and realizing that under the present share structure there are less than 500 Million available shares, most of them already committed to LaJolla, how do you envision the completion of the Dutchess Agreement without a R/S?
As a reference, IF all of the current 500 Million shares were available, it would still require a pps of .14 to complete the deal.
-Direct to the question, how do you envision the completion of the Dutchess Agreement without a R/S? I am hopeful that the price will continue to go up. However, if this does not happen I would rather vote for more shares without a r/s. Much depends on the pipeline products (stat, ov, & Ret HA). If these products can generate a greater revenue stream and if DNAP can control their costs to a degree earnings will improve and perhaps push the stock price up. To the point I feel it’s early to consider a r/s because it does not get you on an exchange and that is the main reason for a company at this stage to consider a r/s.
I hope that clarifies the points that I made.
Big Blue
mikenickels,
Either a r/s or an increase in shares could be needed depending on the current pps.
Big Blue
To date there was not a vote on the r/s.
Big Blue
Thanks Chris. It would be nice to have 3 cheers and a few drinks some day.
Big Blue
Will DNAP Last To See The Fruits Of EPO?
Disclaimers:
1) I do own shares in DNAP.
2) This is my opinion based on information that can be found in DNAP SEC filed documents.
3) This information is directed to and applies to the long investor. Due to the fact that traders like volatility / high Beta, as well as, normally having a short term position this information is not pertinent to their position.
4) Lastly this is not a commentary on the pps direction. This is mainly a commentary on company survival.
Statement:
Those that have read my posts know that I am not fond of emphatic dogma based on little information. I have held true to this for both the optimist and the pessimist. I do not like to conjecture written as fact for very obvious reasons; therefore, you will not see that here.
Will DNAP Last To See The Fruits Of EPO?
The plausible answer to the titled question, Will DNAP Last To See The Fruits Of EPO?, is yes. The reasoning is based on funding from Dutchess Private Equities Fund, L.P.. Simply put the Beth Israel deal adds 2,150,000 in expense over the next 7 years assuming that all the milestones are hit on time (even if they are not hit on time the cost of the contract is minimal. It’s the cost of operation that is the concern.). Cost of operation using the applicable measure of Net loss for 2004 is 3,734,982 on 785,632 in sales. Share dilution with the Dutchess Agreement will provide DNAP with 35 million. To believe in a plausible yes you must assume that net losses will be below 4.5 to 5. Personally, I believe this is likely due to the fact that there are other projects in the pipeline, sales have increased year over year, and net loss has decreased year over year. The next question is will DNAP be able to market and sell their new product. This will likely be farmed out. As stated in the 8K DNAP retains this option. Therefore, if the first commercial sale of a Licensed Product in Asia or S. America is in December 2011 and the First commercial sale of Licensed Product in US/Western Europe is in December 2012 it is reasonable to assume the company will be able to survive and stave off bankruptcy.
Should DNAP R/S?
This is actually a more difficult question. If the means is to increase the price to reap a greater return on share dilution the answer would be yes for the company but no for the investor. If the reason is to get on a major exchange the r/s would have to get the price to 3 or 4 (depending on the exchange)due to minimum bid requirements and as of right now the minimum income requirements are too high for DNAP. So it is likely that any push for a r/s is for greater returns for share dilution. As of right now I probably will not be voting for a r/s.
People should do their own DD and not base their investment choice based on what I have written here. I intend to stay with DNAP for the long haul due to the opinion their science is at a precipitous mountain to be and will be climbed in the very near future.
Good luck and God bless to all,
Big Blue
Welcome aboard!
Big Blue
*You see some of these people posting for weeks and then all of a sudden they disappear. Don't you find that odd?*
Welcome to the board! As to your aforementioned question, I can only speak for myself, and to that, life gets in the way. I would like to post and read more but I can not be here everyday.
Big Blue
Logickle,
Try:
http://www.otcbb.com/
or thelion.com
Blue
thelion.com
5 day prediction on DNAP:
http://www.tradetrek.com/NN/default.asp?symbol=DNAP
Bump from 24154
To the bashers, I hope that you all realize the weight of the PR of 4/5. This is the first PR of its kind for DNAP in that they will be creating / enhancing a drug and to the point will have exclusive rights to a drug that already has several patents. This appears to essentially give DNAP 8 patents from 0 because it is exclusive. There are those that state, “well, there is no time table”. This is true as far as we know; however, we are not privy to everything and PT-401 is already discovered. Plus, DNAP’s enhancements will come from tech that they already have. How much (blind) faith do you need to think that Harvard would agree to an exclusive deal that will not produce? Some perhaps…but not much. The PR is not a guarantee for revenue…this also is true, but it is the best news that DNAP has ever (IMHO) come out with. Look at the facts and not conjecture:
We have an exclusive deal with one of the most reputable medical organizations in the world.
We have essentially picked up the rights to several patents.
We are working on a drug that already has a billion dollar market in a lesser form.
Lastly, we are working on a drug that the FDA as already approved the core form and application for.
I wish the honest well and the misguided peace, enlightenment, and a clean pure soul before you pass.
Big, I love this stuff, Blue
_____________________
"Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin," stated BIDMC's Dr. Arthur J. Sytkowski, who holds patents related to the new "Super"-EPO. "We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug."
The human gene that produces EPO was cloned in 1985, and, in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN®, a drug that many credit for the rise of Amgen in the 1990s as one of the world's most successful biotechnology companies ever.
Patients undergoing certain therapies or with certain conditions are often rendered anemic, meaning their red blood cell count drops dramatically. Without adequate amounts of erythropoietin in the blood, red blood cells are not regenerated efficiently, and there are too few red blood cells to deliver oxygen sufficiently throughout the body. Erythropoietin has been approved by the U.S. Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Anemia leaves patients tired, often impairing their ability to work or perform even routine tasks and over the last decade, EPO has proven to improve quality of life and overall fitness of those patients.
In 1995, Dr. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess, was awarded the first in a string of eight patents covering methods of producing and using recombinant protein multimers with increased biological activity. In these patents, which are subject of the exclusive DNAPrint license announced today, Dr. Sytkowski described a new dimer (double) form of EPO -- "Super"-EPO, that elicited a heartier, more predictable hematocrit (red blood cell count) response, constituting a significant improvement over existing EPO technology.
Bump. Patent Movement
As promised, I stated that I would update the board from time to time on DNAP Patent movement. By the term movement I mean that there has been another step initiated by DNAP or the US Patent Office. This movement may be a non-final rejection, responses, forwarding information, etc. However, movement means that we are closer to the potential of getting a patent. I hope the board finds this information helpful.
Big Blue
Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data
US: 09/964,059; Movement on: 04-01-2005
Methods for the Identification of Genetic Features for Complex Genetics Classifiers
US: 10/120/804; Movement on: 03-28-2005
Compositions and Methods for Detecting Polymorphisms Associated with Pigmentation
US: 10/156,995; Movement on: 04-04-2005
Compositions and Methods for Inferring a Response to Statin
US: 10/188,359; Movement on: 03-30-2005
Brother,
I was about as clear as can be. What's your question? Perhaps read post 24619 and know that it works both ways.
Blue
My streamer showed that too a couple of minutes ago....it showed a 453% gain!
Blue
Just Curious
Does anyone know the all time top volume day for DNAP?
We are currently at: 125.0 mil.
Blue
Hi Miss Scarlet,
It would be great if we had a run-up like that! I'm with you on this one, God willing it would be great but I do not expect it.
Today is turning out to be....interesting. Its expected that people would take profits today but we are already at 77mil shares with a current ask of .0212.
Warmest regards,
Blue
Hey Brother,
Regarding this quote:
Do you all remember the huge run up of the Business to Business stocks (CMGI,ARBA) that ran up to $300+ a share without any meaningful revenues? The same thing will happen here.
I hope you're right but, to be plain, do not post crap like this here. It makes you no better than others on the other side. I have enjoyed some of your posts but the aforementioned goes way too far. I'm sure you understand why.
Big Blue
Up 93%.
Big Blue
86% up.
Big Blue
Up 20% Already!
Big Blue
Critical voices are fine. However, when someone spouts opinion as fact there is a problem. Plus, civility wouldn't hurt either. Most who criticize lack the wisdom to temper their tone to get their point across. Without civility most who listen will likely build defensive walls and tune out the underlining message. As I have stated before, most on this board understand the risks. Lastly (and this maybe the most important point) make absolutely no mistake, short term traders are 100% indifferent to long-term risk; therefore, when a self proclaimed technical trader preaches of long term impending doom, it begs the question, why. Are they being magnanimous or are they being self serving?
Warm regards,
Big Blue
I think its great to see so many of the pending patents moving. Since the start of 2005 it just seems that there is a renewed focus to finalizing one of the pending patents. Of course the press release earlier this month gives DNAP the rights to an estimated 8 patents with our exclusive agreement with the Harvard affiliate!
Big Blue
Patent Movement
As promised, I stated that I would update the board from time to time on DNAP Patent movement. By the term movement I mean that there has been another step initiated by DNAP or the US Patent Office. This movement may be a non-final rejection, responses, forwarding information, etc. However, movement means that we are closer to the potential of getting a patent. I hope the board finds this information helpful.
Big Blue
Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data
US: 09/964,059; Movement on: 04-01-2005
Methods for the Identification of Genetic Features for Complex Genetics Classifiers
US: 10/120/804; Movement on: 03-28-2005
Compositions and Methods for Detecting Polymorphisms Associated with Pigmentation
US: 10/156,995; Movement on: 04-04-2005
Compositions and Methods for Inferring a Response to Statin
US: 10/188,359; Movement on: 03-30-2005
It is entertaining. Thanks for the info Chris.
Miss Scarlet,
No apologies needed! Truly laughing out loud!
My, “Compose yourself” was meant as a joke.
My warmest regards,
Blue
Miss Scarlet,
Compose yourself. That is very unlike you ….but very funny. I admit that I am glad to see the some of the negative dogmatic rhetoric removed from this board.
Big Blue
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Beth Israel Deaconess Medical Center License Agreement
From April's 8K.
The feel-good is still lingering in me from this one.
Big, Blue
Effective April 4, 2005, the Registrant entered into a License Agreement (the Agreement) with Beth Israel Deaconess Medical Center, a Massachusetts nonprofit corporation (Beth Israel) to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO).
EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the currently marketed forms are manufactured using recombinant DNA technology and are used to treat anemia or low blood cell count. Under the Agreement, Beth Israel has granted the Registrant an exclusive license to United States and foreign patents related to certain forms of EPO. The Registrant has the right to develop, use, market and sell products derived from the licensed patents.
In exchange for the license, the Registrant paid Beth Israel a $25,000 signing fee and agreed to make certain milestone payments linked to its progress in developing marketable products from the licensed technology. The total of payments, if all milestones are reached, is $2,150,000. The milestone payments are nonrefundable. Up to $200,000 of this amount is creditable against future royalties. In addition to the milestone payments, the Registrant must also pay Beth Israel an annual royalty of 4% of the net sales of all products developed from the licensed technology. A minimum royalty payment of $100,000 a year is due upon the commencement of commercial sales in any territory worldwide.
Supreme Court Reviewing Drug Patents
Interesting related read. Blue
Wednesday April 20, 12:09 pm ET
By Hope Yen, Associated Press Writer
Supreme Court Reviews How Far a Patent Can Go to Thwart Rival's Efforts to Conduct Drug Research
WASHINGTON (AP) -- Pharmaceutical companies must have flexibility to conduct research into potentially ground-breaking new medicines, the Supreme Court was told Wednesday, as it heard arguments on how far a patent can go to thwart a rival firm's efforts to develop new drugs.
The court considered the case of Integra LifeSciences Holdings Corp., which accuses Germany's Merck KGaA of infringing a patent it holds on certain molecules Merck is using for research. Merck, which isn't related to the U.S. company, says a federal law gives it leeway to experiment.
"You don't spend millions on toxicity studies unless you have a safe drug candidate," said Joshua Rosenkranz, an attorney for Merck, arguing that companies need room for trial and error without overly burdensome restrictions.
But Mauricio Flores, Integra's attorney, argued that a jury properly found that Merck researchers had overstepped their bounds since Integra held a patent. "Chicken embryos have nothing to do with safety," he said, suggesting that most of the company's work was a fishing expedition.
Most justices appeared ready to ask the lower court to take a second look at its ruling, expressing concern that patent protections that are too strong will stifle valid research. All nine justices participated in the argument, suggesting the full court would rule on the case.
In January, Justices Sandra Day O'Connor and Stephen Breyer had removed themselves in the vote to hear the case. The two own shares in the U.S.-based Merck & Co., which was affiliated with Merck KGaA in the 1800s, but the companies are now separate.
The dispute pits large drug companies such as Eli Lilly & Co., Wyeth and Pfizer Inc., which seek greater flexibility to produce innovative new medicines, against smaller biotech firms who say they are entitled to strong legal protection in the highly competitive industry.
A ruling for Integra would "restrict significantly the development of new drugs," argues the Bush administration, which filed a brief backing Merck. "A researcher aware of a promising new cure involving a patented invention could not undertake the research necessary to develop the drug."
The case centers on a patent held by Integra, which is based in Plainsboro, N.J., that was set to expire by 2006. Integra sued for patent infringement after Merck set up animal trials for a promising cancer therapy as a first step in a decade-long plan toward possible approval.
The peptides, or biological molecules, contain a specific amino acid sequence that researchers hope could inhibit tumors.
At issue is whether Integra's patent prohibits Merck's from beginning research into a potential new anticancer drug, even if the drug could not feasibly be marketed until after the patent expired.
Merck contends it was entitled to the "head-start" research under a Food and Drug Administration exemption for studies "reasonably related" to a future drug application, saying it would promote the innovation of cutting-edge treatments while respecting the rights of patent holders.
The Washington-based U.S. Court of Appeals for the Federal Circuit, however, ruled that the FDA exemption did not extend to exploratory research -- only later-phase, human trials typically involving generic drugs. It reasoned that Congress intended only to promote the growth of generics when it passed the exemption in 1984.
AARP, the advocacy group for people 50 and over, argues in filings that the case has important implications for older Americans amid skyrocketing prescription drug costs.
"If this decision stands, the inevitable effect will be that the costs of drug development will be driven up even further and it will serve to delay the development of new medicines," the group states.
But smaller firms such as Invitrogen Corp., which develops scientific tools for use in drug research, counter that their $26 billion industry would go bankrupt if larger companies are given freedom to poke around their patented work without paying a licensing fee first.
"The patent system, as it presently operates, provides the incentive necessary to fuel the development of innovative and beneficial research tools by granting an inventor the exclusive right to control the use of his invention for a limited time," Invitrogen, based in Carlsbad, Calif., writes in its friend-of-the-court filing.
The case is Merck v. Integra Lifesciences, 03-1237.
Supreme Court: http://www.supremecourtus.gov/
LOL! Very clever.
Big Blue
Easyman51,
Yes, it appeared to be at the end of the trial to me too.
The interesting point that led me to place this on the board was that I am estimating the information to be from 2002 and back then they were looking for a partner. To the point, DNAP is who they selected and it appears after very careful consideration and possibly beating out several companies considering we are talking about 3 years. As I and others on this board have stated, it is of note that Havard / Beth Israel Deaconess Medical Center selected DNAPrint. Important note, I found no other company related to PT-401 in a partnership with Beth Israel Deaconess Medical Center prior to DNAP's relationship with them.
State of Development:
BIDMC seeks a corporate partner to aid in the development, including scale up and primate studies, of these proteins.
Big Blue
Off the Harvard Website
Looks like it was from 2002 but its an interesting read considering this months PR.
Big Blue
http://research.bidmc.harvard.edu/TVO/tvotech.asp?Submit=List&ID=579
Treatment for Anemia: Modified and Improved Erythropoietin-Like Proteins
Category: Therapeutics
KeyWords: Chemotherapy;
BIDMC ID: 23
Abstract:
Erythropoietin (EPO) is a hematopoietic growth and differentiation factor that is key to maturation of red blood cells. EPO is produced in specialized kidney cells and the vast majority of patients with end stage renal disease experience anemia due to the inadequate supply of EPO. Several recombinant EPO products are currently used for the treatment of anemia and sales of EPO products topped 6 billion dollars in 2001. This invention describes novel EPO-like fusion proteins. These multimeric forms of EPO display a longer circulating half-life and increased potency. The patents broadly claim methods of increasing the biological activity of any suitable peptide.
Inventor: Dr. Arthur Sytkowski
Commercial Opportunity:
These novel EPO-like fusion proteins are useful for the treatment of anemia experienced by dialysis patients as well as patients receiving chemotherapy.
Competitive Advantages:
The novel EPO-like proteins have a prolonged plasma half-life and a higher potency than other EPO products and thus will likely require less frequent administration.
Related Publications:
State of Development:
BIDMC seeks a corporate partner to aid in the development, including scale up and primate studies, of these proteins.
Related Technology URL:
Patent Status:
US Patent 6,187,564 B1, issued 2/13/01. US Patent 5,919,758 issued 7/6/99. Foreign applications pending.
TVO Contact Info:
Christine Jost-Price
Associate Director TVO
cjost@bidmc.harvard.edu
Phone: 617-667-4239 Fax: 617-667-0646
Beth Israel Deaconess Medical Center
Technology Ventures Office Room: FN-218
330 Brookline Avenue
Boston, MA 02215
Post #24263 by cloud.
Regards and take care,
Blue
Ann,
It may be more recent but Family Tree Legends (your PR) and Family Tree DNA (Aero's) are not the same company. I think someone has already pointed that out. Don't mislead people. I guess that has become my mantra for this board.
Big Blue
perhaps, october 2007 .0001
Thanks easymedicine. Now the board knows when you say that it WILL happen you are pointing to perhaps, october 2007 .0001.
Big Blue